Clinical Trial Update: A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating SAR443579, a natural killer cell engager, in combination with different agents for acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SAR443579

Snippet

Sponsor: Sanofi | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED